The DOI matches its Crossref record.
Recurrent Ovarian Cancer
Abstract
Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non–cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients’ quality of life, and evidence addressing the potential benefits of longer-term treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ovarian Cancer: A Heterogeneous Disease
Kossaï, M., Leary, A., Scoazec, J.-Y., & Genestie, C. (2018) · Pathobiology · doi:10.1159/000479006 · Cited by 388
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Self-citationRole of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
Wang, J., & Wu, G. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558288 · Cited by 291
Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients
Kayl, A. E., & Meyers, C. A. (2006) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/01.gco.0000192996.20040.24 · Cited by 254
Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., & Ioannidis, J. P. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj443 · Cited by 187
Metadata
- Authors
- Herzog, T. J.
- Venue
- Clinical Cancer Research
- Published
- 2004-11-15
- Volume
- 10
- Issue
- 22
- Pages
- 7439-7449
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2127952549
- Cited by
- 188
- References
- 0
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0683
- The paper
- Herzog, T. J. (2004). Recurrent Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.